Incyte Analyst Price Targets - Benzinga

Incyte Corp

INCYNASDAQ

Trade with Public

Trade with Public

$113.27

1.701.52%

概要ニュース業績予想イベント目標株価財務センチメント株主構成比較オプション株式レポート

© 2026 Benzinga | All Rights Reserved

Incyte Analyst Price Targets

Wall Street analyst price targets and consensus rating for Incyte (INCY).

Price Target Range — 9 Quarters

Analyst Consensus — 23 Analysts

11Buy

12Hold

Consensus RatingBuy# Analysts23Avg. Consensus PT$117Upside to Avg. PT+3.0%

Rating Trend — Last 9 Months

Recent Analyst Actions

すべての評価を見る →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 14, 2026	Truist Securities	Srikripa Devarakonda	PT Raise	Hold	$105→$115
Oct 13, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	Maintained	Buy	$152
Oct 8, 2026	RBC Capital	Brian Abrahams	PT Raise	Sector Perform	$109→$114
Oct 5, 2026	Stifel	Stephen Willey	PT Raise	Buy	$145→$157
Oct 1, 2026	Wells Fargo	Derek Archila	PT Raise	Equal-Weight	$116→$128
Sep 28, 2026	JP Morgan	Jessica Fye	PT Raise	Neutral	$120→$123
Sep 28, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	PT Raise	Buy	$150→$152
Sep 22, 2026	RBC Capital	Brian Abrahams	Maintained	Sector Perform	$109
Aug 20, 2026	Canaccord Genuity	John Newman	Initiate	Buy	$152
Aug 20, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	Maintained	Buy	$150
Aug 17, 2026	Piper Sandler	Allison Bratzel	PT Raise	Overweight	$110→$130
Aug 4, 2026	Mizuho	Salim Syed	PT Raise	Outperform	$121→$137
Aug 3, 2026	Leerink Partners	Andrew Berens	PT Raise	Outperform	$131→$155
Aug 3, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	Maintained	Buy	$150
Jul 29, 2026	RBC Capital	Brian Abrahams	PT Raise	Sector Perform	$99→$109
Jul 29, 2026	Guggenheim	—	PT Raise	Buy	$136→$150
Jul 29, 2026	BMO Capital	Evan Seigerman	PT Raise	Market Perform	$112→$130
Jul 29, 2026	Barclays	Etzer Darout	PT Raise	Overweight	$134→$139
Jul 29, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	PT Raise	Buy	$140→$150
Jul 23, 2026	JP Morgan	Jessica Fye	PT Raise	Neutral	$105→$110

More with Benzinga EdgeGet Access

Analyst Ratings News

Why Is Arcutis Biotherapeutics Stock Surging Thursday?

Cantor Fitzgerald initiated Arcutis (ARQT) at Overweight with a $48 target, citing Zoryve's potential for $3.5B in peak sales.

Vandana Singh

PRO
Truist Securities Maintains Hold on Incyte, Raises Price Target to $115

Truist Securities analyst Srikripa Devarakonda maintains Incyte (NASDAQ:INCY) with a Hold and raises the price target from $105 to $115.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Incyte, Maintains $152 Price Target

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Incyte (NASDAQ:INCY) with a Buy and maintains $152 price target.

Benzinga Newsdesk

PRO
RBC Capital Maintains Sector Perform on Incyte, Raises Price Target to $114

RBC Capital analyst Brian Abrahams maintains Incyte (NASDAQ:INCY) with a Sector Perform and raises the price target from $109 to $114.

Benzinga Newsdesk

PRO
Stifel Maintains Buy on Incyte, Raises Price Target to $157

Stifel analyst Stephen Willey maintains Incyte (NASDAQ:INCY) with a Buy and raises the price target from $145 to $157.

Benzinga Newsdesk

PRO
Wells Fargo Maintains Equal-Weight on Incyte, Raises Price Target to $128

Wells Fargo analyst Derek Archila maintains Incyte (NASDAQ:INCY) with a Equal-Weight and raises the price target from $116 to $128.

Benzinga Newsdesk